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Abstract
Objectives Recent safety concerns regarding gadolinium-based contrast agents (GdCAs) concluded with the suspension of some
agents from the European market, yet a clinical consequence remains unknown. We used electronic health records to investigate
the incidence of potential toxicity to gadoteric acid (Dotarem®) within our local population, including those with renal insuffi-
ciency (RI).
Methods Data for patients who underwent contrast-enhancedMRI were identified, stratified by renal function at time of scan and
retrospectively followed using routinely collected health data. Searches performed were: records of hypersensitivity reactions;
diagnoses of nephrogenic systemic fibrosis (NSF); onset of chronic pain, a symptom that has been associated with NSF and the
theorised gadolinium deposition disease (GDD); and post-contrast acute kidney injury (PC-AKI). Comparisons were made
between patients and controls (those who underwent non-contrast scans) via chi-square and ANOVA statistical tests.
Results Of the 22,897 contrast-enhanced MRI scans performed locally from 2004–2016 (adult, n = 22,325 and paediatric,
n = 572), 14% were performed on patients with RI (30 ≤ eGFR < 60, n = 2,622; 15 ≤ eGFR < 30, n = 464; eGFR < 15, n =
123). Two adult patients (0.01%) suffered hypersensitivity reactions. Zero cases of NSFwere reported, with an average follow-up
time of 6.0 ± 2.5 years (range, 8 months–15 years). Analysis failed to highlight statistically higher rates of chronic pain onset post-
MRI (adult: p = 0.777, paediatric: p = 0.578), or PC-AKI (adult: p = 0.566, paediatric: p = 0.841), in the patient groups compared
to controls.
Conclusions These data indicate that administration of gadoteric acid to RI patients does not result in a higher rate of signs or
symptoms that may be associated with gadolinium toxicity when compared to controls.
Key Points
• Following 22,897 administrations of gadoteric acid to a local population, there was no association with symptoms that may be
associated with gadolinium toxicity.
• Zero cases of nephrogenic systemic fibrosis were reported following 3,209 gadoteric acid administrations to a cohort of renally
insufficient patients.
• A low number of hypersensitivity reactions were observed (0.01%) and no higher rate of chronic pain or post-contrast acute
kidney injury were noted when compared with a control cohort of non-contrast-enhanced examinations.
Keywords Magnetic resonance imaging, . Medical record linkage, . Contrast media, . Renal insufficiency
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Introduction
Macrocyclic and linear gadolinium-based contrast agents
(GdCAs) are routinely used in magnetic resonance imaging
(MRI) to speed imaging and aid diagnosis. The stability of
these agents varies, with the macrocyclic, ionic agents consid-
ered the most thermodynamically and kinetically stable, while
linear, non-ionic agents, are considered less so [1]. In general,
GdCAs have excellent safety profiles with immediate hyper-
sensitivity reactions reported as between 0.01% and 2.4% [2,
3], yet the longer term safety of these agents has recently come
under intense scrutiny. The deposition of gadolinium within
the body following exposure to these agents has been proven
[4–6], and appears to be dependent on factors such as agent
stability and patient renal function. Whilst no clinical conse-
quence has been confirmed, the term gadolinium toxicity has
been ascribed to a broad range of likely pathologies [7].
Nephrogenic systemic fibrosis (NSF) was definitively linked
to the administration of some GdCAs in patients with renal
insufficiency (RI) in 2006 [8, 9]. This incurable skin-fibrosing
condition, often accompanied with chronic pain [10], typically
arises within 2–10 weeks [11] of contrast administration, and is
seen with greater frequency in patients with more severe RI at
the time of exposure. NSF was found to be directly related to
the stability of GdCAs and, as such, in 2010 the European
Medicines Agency (EMA) [12] and US Food and Drug
Administration (FDA) [13] established guidelines and classi-
fied the agents based on their risk of inducing NSF. Post-
contrast acute kidney injury (PC-AKI) is a sudden deterioration
in renal function post-contrast media administration in the ab-
sence of other nephrotoxic events [14] and, although the devel-
opment of PC-AKI following exposure to GdCAs remains
highly disputed due to inconsistent study protocols, there is
evidence to suggest that GdCAs can induce PC-AKI [15–17].
More recently, gadolinium has been found to accumulate in
the body regardless of renal function [4, 18, 19]. The highest
concentrations of gadolinium have been seen following expo-
sure to the least thermodynamically stable GdCAs [6, 20, 21]
and total concentrations within the CNS display an inverse
correlation with renal function [22]. Following an extensive
review, the EMA has ‘confirmed recommendations to restrict
the use of some linear gadolinium agents used in MRI body
scans and suspend the authorisation of others’ [23]. Clinical
consequences of a theorised gadolinium deposition disease
(GDD) have not yet been confirmed but case reports and pub-
lished support group surveys suggest symptoms could be rem-
iniscent of NSF [24–26]. The development of symptoms such
as headaches, bone/joint pain and skin changes appear to
occur earlier, with typical onset times reported between hours
and days post-contrast-enhanced MRI [24, 25].
As the renal pathway is the predominant excretion mecha-
nism of most GdCAs, patients with RI are considered at high
risk of the above signs and symptoms of gadolinium toxicity
and therefore a population of great interest. However, due to
changes in guidelines and clinical practice, the use of GdCAs
in populations with RI has declined dramatically [27, 28], and
instigating contrast-enhanced MRI clinical trials would be
challenging. In cases where the diagnostic information is un-
available via non-contrast images and the clinical benefit-to-
risk ratio is favourable, low risk macrocyclic GdCAs have
continued to be administered.
Locally, patient-specific electronic health records have
been collated over many years, and as such, the aim of this
study was to use this data in a unique way to follow adult and
paediatric patients, particularly focussing on those with RI,
who have been exposed to gadoteric acid (Dotarem®,
Guerbet) in order to identify any hypersensitivity reactions
or symptoms that may be associated with gadolinium toxicity
such as NSF, PC-AKI and/or chronic pain.
Materials and methods
Ethical approvals
Approval for this work was granted by the East of Scotland
Research Ethics Committee under the collective ReDVA pro-
ject (a European Union’s 7th Framework Program grant agree-
ment no. 324487). Whilst the routinely collected NHS patient
data used for this study is not patient-consented, the research is
approved byNHSCaldicott Guardian for anonymised analysis
within the SafeHaven secure IT environment.
Data
Local electronic patient data were used to identify and compile
patient timelines. Patient data for those who had undergone
solely gadoteric acid-enhanced scans were included into the
study cohort. Data from those patients who had undergone
solely non-contrast MRI were included as a control cohort.
Accident & Emergency (A&E) admissions, biochemistry re-
cords (serum creatinine), dermatology and medication pre-
scriptions were then gathered and linked for the entire study
population.
Demography data such as gender and date of birth were
provided for each patient in the study cohort. In combination
with the examination date, age at scan was calculated. Renal
function was described by serum creatinine for paediatric pa-
tients (0–17 years), while for adults (18+ years) serum creat-
inine was converted to estimated glomerular filtration rate
(eGFR) via the Modification of Diet in Renal Disease
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(MDRD) study equation. Data collection was performed by a
qualified data analyst, and following anonymisation, data
linkage was performed by an experienced medical researcher
using Microsoft Excel (2013 version, Microsoft) within the
SafeHaven secure IT environment.
Patient data
In total, the electronic records for 40,411 MRI scans and cor-
responding biochemistry, dermatology and prescription data
were gathered and divided into contrast and non-contrast
MRI. 1,333 scans pertaining to 947 patients were excluded
due to documented use of GdCAs other than gadoteric acid.
Within the local area between 2004 and 2016, 22,325
contrast-enhanced MRI were performed on 15,377 adult pa-
tients (average age, 55.6 ± 16.1 years; range, 18–97 years;
53.3% female) and 572 contrast-enhanced scans were per-
formed on 370 paediatric patients (average age, 11.4 ± 5.3
years; range, 0–17 years; 51.4% female). Further demograph-
ic data are outlined in Table 1.
For contrast scans performed on adults, eGFR values were
calculated from serum creatinine at the time point closest prior
to MRI and used to stratify scans accordingly; stages 1/2
(eGFR ≥ 60 ml/min/1.73 m2, n = 19,168), stage 3
(30 ml/min/1.73 m2 ≤ eGFR < 60 ml/min/1.73 m2, n =
2,570), stage 4 (15 ml/min/1.73 m2 ≤ eGFR < 30 ml/min/
1.73 m2, n = 464) and stage 5 (eGFR < 15 ml/min/1.73
m2, n = 123). Scan data for paediatric patients was stratified
into two renal function categories: normal (n = 520) and im-
paired (n = 52) dependent upon interdepartmental age and
gender-modified serum creatinine reference values.
Similar stratification by age and renal function categories
was performed for the control data of non-contrast
examinations.
Hypersensitivity reactions
Hypersensitivity reactions were identified by any records of
admission to A&E within a day of contrast-enhanced MRI
with presenting symptoms that matched known reactions to
gadoteric acid as given in the prescribing information and/or
any general hypersensitivity reaction (Table 2).
Potential toxicity signs
A search was performed on the dermatology records between
1 January 2004 and 30 November 2016 with the aim of iden-
tifying a recorded NSF diagnosis following any contrast-
enhanced MRI scan. Chronic pain, a symptom sometimes
associated with both NSF and GDD, was determined by the
onset of new and regular prescriptions for chronic pain med-
ication (British National Formulary Chapters 4.7.3 and 10.1.1)
within 7 days post-MRI. Cases of PC-AKI were defined as an
increase in serum creatinine greater than 25% from baseline
within 3 days post-MRI in accordance with European Society
of Urogenital Radiology (ESUR) guidelines [14] that were in
place when this study was conducted.
Statistical analysis
Statistical analysis was performed in SPSS statistical package
(version 21.0, IBM SPSS). Statistical diagnostics were first
performed to ensure the appropriate tests were used. Mann-
Whitney and ANOVA tests with post-hoc analysis were per-
formed to compare cohort demographics. Chi-squared tests
were used to compare differences in rates of new chronic pain
medication prescriptions between cohorts. ANCOVA testing
was used to analyse changes in serum creatinine for both
contrast and non-contrast scans across eGFR categories. Chi
square and Fisher’s exact tests were used to compare the inci-
dence of PC-AKI. A p-value of ≤ 0.05 was considered statis-
tically significant.
Results
Study cohort – adults
A total of 37,813 contrast and non-contrast scans performed
on a cohort of 21,770 adult patients were identified for anal-
ysis. 22,325 scans were contrast-enhanced, of which 14%
were performed while the patient was deemed renally
insufficient.
The average age at scan of all patients was significantly
different between renal function categories. Age tended to
increase with increasing RI (stages 1/2, 53.3 ± 15.4 years;
stage 3, 69.6 ± 11.6 years; stage 4, 73.1 ± 12.7 years), but
the average age decreased in the stage 5 category (60.5 ± 15.3
years). The average age of patients in stages 1/2 and 3 under-
going contrast-enhanced scans was higher when compared to
those undergoing non-contrast scans (p < 0.0005), but this
trend did not continue into stage 4 or 5 (p = 0.805 and
p = 0.060, respectively). There were no statistically significant
gender biases across renal function categories observed within
the contrast group. For the non-contrast cohort, there was only
a higher proportion of females than males in the stage 3 cate-
gory (p < 0.0005). When comparisons were made between
those having received contrast and those not, a significantly
greater proportion of females underwent non-contrast scans in
stages 1/2 and 3 than males (p < 0.0005).
Hypersensitivity reactions
Two adult patients (0.01%) were admitted to A&E with hy-
persensitivity reactions within a day of contrast-enhanced
MRI. The first patient presented with a headache that occurred
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following their first contrast-enhanced MRI. The patient
underwent no further scans. The second patient presented in
an anxiety state following their first contrast-enhanced MRI
but did go on to undergo two further contrast-enhanced scans
with no reactions.
NSF
With an average follow-up time of 6.0 ± 2.5 years (range, 8
months–15 years), zero cases of NSF were diagnosed follow-
ing the 3,157 gadoteric acid-enhanced MRI performed on pa-
tients with RI.
PC-AKI
Serum creatinine levels within 3 days pre- and post-MRI were
available and percentage changes thus calculated for 2,105
contrast and 970 non-contrast scans. After controlling for the
dependence of creatinine changes on eGFR category, there
was no statistical difference in percentage changes of creati-
nine between contrast or non-contrast scans (-0.40% vs.
0.61%, p = 0.273). When this analysis was limited to only
those scans performed on patients with renal function
categorised as stage 4 or 5, those undergoing a non-contrast
scan experienced an average serum creatinine increase of
7.31%, while the serum creatinine of those undergoing con-
trast scans decreased by an average of -4.40% (p = 0.023).
There was no statistical difference in cases of a greater than
25% increase in serum creatinine post-MRI observed (Fig. 1)
regardless of renal function or whether contrast was adminis-
tered or not (p = 0.566).
GDD
A total of ten (0.026%) cases of new and regular chronic pain
medication prescriptions were noted following either contrast
or non-contrast MRI. Seven of these were contrast-enhanced
MRI. All patients had normal renal function at the time of
scan. The rate was not statistically higher regardless of renal
function or whether contrast was administered (p = 0.777).
Paediatrics
A total of 1,265 scans performed on a cohort of 698 paediatric
patients were identified for analysis. 572 scans were contrast-
enhanced, of which 9% were performed while the patient was
deemed renally insufficient.
Within both the normal and RI categories, the average age
at scan was statistically higher in those undergoing contrast
scans compared with non-contrast scans (p < 0.0005 and
p = 0.015, respectively). There was no significant difference
in gender proportions (p = 0.180) regardless of renal function
or contrast group.
Zero paediatric patients were admitted to A&E with hyper-
sensitivity reactions within a day of contrast enhanced MRI.
After monitoring for an average time of 6.2 ± 2.4 years (range,
1–10 years), there have been zero cases of NSF diagnosed
following 52 contrast-enhanced MRIs performed on 32 pae-
diatric patients with RI. Percentage changes in serum creati-
nine did not differ significantly between the contrast and non-
contrast group (0.32% vs. -6.05%, p = 0.113) and there was no
significantly higher rate of increases over 25% observed
(p = 0.841) regardless of renal function or contrast adminis-
tration. One scan out of 1,265 (0.08%) was followed by an
onset of a new, regular chronic pain medication prescription.
Table 2 List of known adverse
events (AEs) to gadoteric acid and
other potential AEs as reported in
the complete Accident &
Emergency (A&E) dataset that
was used to identify appropriate
A&E admission records
Presenting symptom
Known gadoteric acid AE Allergic rash, Angioedema, Anaphylaxis, Anxiety, Arrhythmia, Asthma
attack, Bradycardia, Bronchospasm, Burning sensation, Cardiac
arrest, Coma, Conjunctivitis, Convulsion, Cramp, Cyanosis,
Diarrhoea, Dizziness, Drowsiness, Erythema, Erythroderma,
Exacerbation of asthma, Extravasation, Eyelid oedema, Fatigue,
Fever, Headache, Hyperhidrosis, Hypertension, Hypotension,
Injection site coldness, Injection site pain, Itching, Lacrimation,
Laryngospasm, Malaise, Muscle contracture, Muscle spasm, Muscle
weakness, Nausea, Ocular hyperaemia, Oropharyngeal discomfort,
Pain in extremity, Palpitations, Paraesthesia, Parsomia, Pharyngeal
oedema, Pins and needles, Pruritus, Rash, Salivary hypersecretion,
Serum creatinine increase, Sleepiness, Superficial phlebitis, Syncope,
Tachycardia, Tremor, Urticaria, Vomiting
Other potential AE identified as
reported in A&E dataset
Acute renal failure, Anxiety state, Cardiac arrhythmia, Chronic renal
failure, Dermatitis, Erythema nodosum, Exacerbation of asthma,
Migraine headache, Needlestick, Needlestick wound, Panic attack,
Primary hypertension, Purpura, Pyrexia, Rash, Sinus bradycardia,
Sinus tachycardia, Situational collapse, Supra ventricular tachycardia,
Urticarial rash, Ventricular tachycardia
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At the time of the contrast-enhanced scan, the patient had
normal renal function. The incidence of prescriptions for
chronic pain medicine did not differ significantly across renal
function or contrast group (p = 0.578).
Discussion
‘Gadolinium toxicity’ is a generic term that had been ascribed
to a myriad of signs and symptoms resulting from exposure to
GdCAs, some of which have been confirmed – hypersensitiv-
ity reactions and NSF, whilst others are more debatable – PC-
AKI and chronic pain. After having been deemed at an in-
creased risk of gadolinium toxicity, the administration of
GdCAs to patients with renal insufficiency has declined.
Contrast-enhanced MRI scans may still be performed in this
population if the benefit of information to be gained out-
weighs the potential risk, thus investigations may still contin-
ue retrospectively.
Through health data linkage, the anonymised patient data
from 39,078 MRI scans, performed locally between 2004 and
2016, was linked with patient-specific electronic health re-
cords. Gadoteric acid was administered during 22,897 of these
scans, 3,209 of which were performed on RI individuals. A
low number of hypersensitivity reactions were observed with-
in our adult cohort (0.01%) and none within our paediatric
patients post-contrast exposure. After following these patients
via their health records for an average of 6 years, zero cases of
NSF were identified. Serum creatinine levels for the study
cohort were largely unaffected (Fig. 1), with no statistically
higher rate of PC-AKI following exposure to gadoteric acid
when compared to non-contrast examinations, regardless of
baseline renal function. Across all patients, there has been
no significantly higher rate of chronic pain onset, a symptom
that has been associated with GDD, when compared with
patients who had undergone non-contrast scans.
To the best of our knowledge, this study is one of the largest
and longest investigations into NSF diagnoses in cohorts with
RI following GdCA administration. It is amongst the first to
investigate for an array of potential signs and symptoms of
gadolinium toxicity. No study has previously used data link-
age in this manner to identify hypersensitivity reactions to
gadoteric acid. Traditional adverse event monitoring methods
have estimated reaction rates to gadoteric acid at between
0.12% [29] and 0.97% [30]. Rates of NSF and PC-AKI have
been researched previously, with which this study agrees well.
In particular, no unconfounded cases of NSF have been con-
firmed following gadoteric acid administration [2, 29, 31] and
no significantly higher rates of PC-AKI were observed be-
tween the cohort of patients with RI exposed to gadoteric acid
and those who underwent non-contrast scans only [31]. As
GDD is a recently hypothesised clinical entity, few studies
have investigated for potential symptoms. Whilst this study
has investigated for the incidence of chronic pain onset, sim-
ilar data linkage methodologies have been used to assess for
cerebellar sequelae [32, 33]. In particular, Perrotta et al failed
to observe the occurrence of clinical cerebellar syndrome in
their gadoteric acid-exposed population [32].
Fig. 1 Observed rate of cases
with > 25% increase in creatinine
in adults depending on renal
function andwhether contrast was
administered or not. Numbers
above bars represent the number
of cases with > 25% increase in
creatinine/total number of scans
investigated
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Conversely, other GdCAs have been associated with some
form of gadolinium toxicity. Although the vast majority of
NSF cases have been seen following the administration of
linear agents, there have been unconfounded cases reported
with other macrocyclic agents [12, 34, 35] . In cases of
suspected GDD, chronic pain is a frequent symptom [25] for
which chronic pain medication has been administered in order
to ease symptoms [26]. Available data on GdCA-induced PC-
AKI varies widely, and with small sample sizes it is difficult to
draw definitive conclusions [36], but PC-AKI has been ob-
served following administrations of both gadodiamide [37]
and gadopentetate dimeglumine [38].
Demonstrating that GdCAs can be used safely in this pop-
ulation may improve outcomes for patients with RI. By being
able to examine patients using the full capabilities of MRI, co-
morbidities and complications may be better diagnosed and
treated [39]. Although an MRI-based clinical trial is likely to
be deemed unethical at this time, health data linkage has
allowed MRI-based research to continue in this cohort and
further help to identify any potential clinical consequences
of gadolinium toxicity. It was noted in the EMA’s report [12]
that, regardless of renal function at the time of GdCA admin-
istration, it remains unknown whether later declines in patient
health may trigger gadolinium toxicity symptoms. Thus, it is
imperative to employ a surveillance technique that can accu-
rately monitor patient populations over long periods of time.
Ramahlo et al also suggests that reactions to gadolinium may
depend somewhat on genetics [7]. As such, there is a potential
for further studies to use health data linkage, incorporating
genetic data, where available, to help develop understanding
of how this disease may progress, if at all.
There are limitations to this study. Regarding the collection
of hypersensitivity reaction data, it is possible that by only ex-
amining A&E records somemild adverse events may have been
overlooked. Patients who suffer a mild reaction may present to
their GP or other healthcare providers (e.g. community pharma-
cy) and, although there is potential for these records to also be
examined, they were not available for this study. As NSF aware-
ness increasedwithin the time period of this study, precautionary
methods, such as immediate post-MRI dialysis, may have been
employed thus reducing any potential effects. The retrospective
nature of this study allowed for NSF diagnoses to be determined
only via dermatology records. It is appreciated, however, that
NSF is a multi-factorial pathology and a definitive diagnosis
includes clinical, biochemical and histopathological features
[40], which were unavailable. Serum creatinine changes may
have resulted from other factors that were not controlled for,
such as cardiovascular disease, renal artery stenosis, advanced
age, dehydration and use of nephrotoxic drugs. Averaging se-
rum creatinine levels at precise time points pre- and post-MRI
would have provided a clearer indication of renal function; how-
ever, these data were not available. Following the completion of
this study, it was noted that new guidelines regarding PC-AKI
were published [41] in which the definition of PC-AKI was
amended. As access to the data had expired, the analysis could
not be repeated using the new definitions. Unfortunately, height
data were not recorded and thus the Schwartz formula could not
be used to categorise paediatric renal function. Cohort demog-
raphy differences are unlikely to have impacted results as gad-
olinium toxicity has been shown to have no age, gender or racial
predisposition [11, 42]. It cannot be guaranteed that patients
were administered no other GdCAs, nor sought medical atten-
tion in other institutions. In some cases, patients may not have
consulted their general practitioners or sought any other form of
medical attention. Beyond NSF, a disease profile relating to
gadolinium deposition is unconfirmed so these results are mere-
ly conjecture. Chronic pain and PC-AKI have, however, all been
associated with the administration of GdCAs, and using large
datasets such as this one may be the only way to identify un-
confounded symptoms, if any, caused by the agents.
Cases of potential gadolinium toxicity to gadoteric acid
(Dotarem®) were investigated through the electronic linkage
of health data. None of the 22,897 contrast-enhanced scans per-
formed on adult and paediatric patients, including the 3,209
scans performed on patients with renal insufficiency, resulted
in a diagnosis of NSF. A low number of hypersensitivity reac-
tions post-contrast were observed. There was no statistically
higher rate of chronic pain or cases of PC-AKI observed between
the contrast- and non-contrast-enhanced scans investigated.
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